1
|
Zampaloni C, Mattei P, Bleicher K, Winther L, Thäte C, Bucher C, Adam JM, Alanine A, Amrein KE, Baidin V, Bieniossek C, Bissantz C, Boess F, Cantrill C, Clairfeuille T, Dey F, Di Giorgio P, du Castel P, Dylus D, Dzygiel P, Felici A, García-Alcalde F, Haldimann A, Leipner M, Leyn S, Louvel S, Misson P, Osterman A, Pahil K, Rigo S, Schäublin A, Scharf S, Schmitz P, Stoll T, Trauner A, Zoffmann S, Kahne D, Young JAT, Lobritz MA, Bradley KA. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature 2024; 625:566-571. [PMID: 38172634 PMCID: PMC10794144 DOI: 10.1038/s41586-023-06873-0] [Citation(s) in RCA: 22] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 11/16/2023] [Indexed: 01/05/2024]
Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global pathogen with limited treatment options1. No new antibiotic chemical class with activity against A. baumannii has reached patients in over 50 years1. Here we report the identification and optimization of tethered macrocyclic peptide (MCP) antibiotics with potent antibacterial activity against CRAB. The mechanism of action of this molecule class involves blocking the transport of bacterial lipopolysaccharide from the inner membrane to its destination on the outer membrane, through inhibition of the LptB2FGC complex. A clinical candidate derived from the MCP class, zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms. This chemical class represents a promising treatment paradigm for patients with invasive infections due to CRAB, for whom current treatment options are inadequate, and additionally identifies LptB2FGC as a tractable target for antimicrobial drug development.
Collapse
Affiliation(s)
- Claudia Zampaloni
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Patrizio Mattei
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Konrad Bleicher
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
- SixPeaks Bio, Basel, Switzerland
| | - Lotte Winther
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Claudia Thäte
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
- Preclinical Sciences and Translational Safety, Janssen Pharmaceutica, Beerse, Belgium
| | - Christian Bucher
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Jean-Michel Adam
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
- AutoChem R&D, Mettler-Toledo International, Greifensee, Switzerland
| | - Alexander Alanine
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
- Independent consultant, Cambridge, Great Britain
| | - Kurt E Amrein
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Vadim Baidin
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA
| | - Christoph Bieniossek
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Caterina Bissantz
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Franziska Boess
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Carina Cantrill
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Thomas Clairfeuille
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Fabian Dey
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Patrick Di Giorgio
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Pauline du Castel
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - David Dylus
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Pawel Dzygiel
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Antonio Felici
- Discovery Microbiology, Aptuit (Verona) Srl, an Evotec Company, Verona, Italy
| | - Fernando García-Alcalde
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Andreas Haldimann
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Matthew Leipner
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Semen Leyn
- Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Séverine Louvel
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Pauline Misson
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Andrei Osterman
- Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Karanbir Pahil
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA
| | - Sébastien Rigo
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Adrian Schäublin
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
- SixPeaks Bio, Basel, Switzerland
| | - Sebastian Scharf
- Roche Pharma Research and Early Development, Informatics, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Petra Schmitz
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Theodor Stoll
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Andrej Trauner
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Sannah Zoffmann
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
- Therapeutics Discovery, Janssen Pharmaceutica, Beerse, Belgium
| | - Daniel Kahne
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA
| | - John A T Young
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
| | - Michael A Lobritz
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
| | - Kenneth A Bradley
- Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
| |
Collapse
|
2
|
Iakovenko RO, Chrenko D, Kristek J, Desmedt E, Zálešák F, De Vleeschouwer F, Pospíšil J. Heteroaryl sulfonamide synthesis: scope and limitations. Org Biomol Chem 2022; 20:3154-3159. [PMID: 35343994 DOI: 10.1039/d2ob00345g] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Heteroaryl sulfonamides are important structural motifs in the medicinal and agrochemical industries. However, their synthesis often relies on the use of heteroaryl sulfonyl chlorides, which are unstable and toxic reagents. Herein, we report a protocol that allows direct oxidative coupling of heteroaryl thiols and primary amines, readily available and inexpensive commodity chemicals. The transformation proceeds under mild reaction conditions and yields the desired N-alkylated sulfonamides in good yields. N-alkyl heteroaryl sulfonamides can be further transformed using a microwave-promoted Fukuyama-Mitsunobu reaction to N,N-dialkyl heteroaryl sulfonamides. The developed protocols thus enable the preparation of previously difficult to prepare sulfonamides (toxic reagents, harsh conditions, and low yields) under mild conditions.
Collapse
Affiliation(s)
- Roman O Iakovenko
- Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences, and Faculty of Science, Palacky University, Šlechtitelů 27, Olomouc CZ-78371, Czech Republic.
| | - Daniel Chrenko
- Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences, and Faculty of Science, Palacky University, Šlechtitelů 27, Olomouc CZ-78371, Czech Republic. .,Department of Chemical Biology, Faculty of Science, Palacky University, Šlechtitelů 27, Olomouc CZ-78371, Czech Republic
| | - Jozef Kristek
- Department of Organic Chemistry, Faculty of Science, Palacky University, tř. 17. listopadu 1192/12, Olomouc CZ-771 46, Czech Republic
| | - Eline Desmedt
- Eenheid Algemene Chemie (ALGC), Vrije Universiteit Brussel (VUB), Pleinlaan 2, 1050 Brussels, Belgium
| | - František Zálešák
- Department of Organic Chemistry, Faculty of Science, Palacky University, tř. 17. listopadu 1192/12, Olomouc CZ-771 46, Czech Republic
| | - Freija De Vleeschouwer
- Eenheid Algemene Chemie (ALGC), Vrije Universiteit Brussel (VUB), Pleinlaan 2, 1050 Brussels, Belgium
| | - Jiří Pospíšil
- Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences, and Faculty of Science, Palacky University, Šlechtitelů 27, Olomouc CZ-78371, Czech Republic. .,Department of Chemical Biology, Faculty of Science, Palacky University, Šlechtitelů 27, Olomouc CZ-78371, Czech Republic.,Department of Organic Chemistry, Faculty of Science, Palacky University, tř. 17. listopadu 1192/12, Olomouc CZ-771 46, Czech Republic
| |
Collapse
|
3
|
Habeshian S, Sable GA, Schüttel M, Merz ML, Heinis C. Cyclative Release Strategy to Obtain Pure Cyclic Peptides Directly from the Solid Phase. ACS Chem Biol 2022; 17:181-186. [PMID: 35015522 DOI: 10.1021/acschembio.1c00843] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The synthesis of large numbers of cyclic peptides─required, for example, in screens for drug development─is currently limited by the need of chromatographic purification of individual peptides. Herein, we have developed a strategy in which cyclic peptides are released from the solid phase in the pure form and do not need purification. Peptides with an N-terminal thiol group are synthesized on the solid phase via a C-terminal disulfide linker, their sidechain-protecting groups are removed while the peptides remain on the solid phase, and the peptides are finally released via a cyclative mechanism by the addition of a base that deprotonates the N-terminal thiol group and triggers an intramolecular disulfide-exchange reaction. The method yields disulfide-cyclized peptides, a format on which many important peptide drugs such as oxytocin, vasopressin, and octreotide are based. We demonstrate that the method is applicable for facile synthesis in 96-well plates and allows for synthesis and screening of hundreds of cyclic peptides.
Collapse
Affiliation(s)
- Sevan Habeshian
- Institute of Chemical Sciences and Engineering, School of Basic Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| | - Ganesh A. Sable
- Institute of Chemical Sciences and Engineering, School of Basic Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| | - Mischa Schüttel
- Institute of Chemical Sciences and Engineering, School of Basic Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| | - Manuel L. Merz
- Institute of Chemical Sciences and Engineering, School of Basic Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| | - Christian Heinis
- Institute of Chemical Sciences and Engineering, School of Basic Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| |
Collapse
|
4
|
Zálešák F, Kováč O, Lachetová E, Št'astná N, Pospíšil J. Unified Approach to Benzo[ d]thiazol-2-yl-Sulfonamides. J Org Chem 2021; 86:11291-11309. [PMID: 34479409 DOI: 10.1021/acs.joc.1c00317] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In this paper, we report a unified approach to N-substituted and N,N-disubstituted benzothiazole (BT) sulfonamides. Our approach to BT-sulfonamides starts from simple commercially available building blocks (benzo[d]thiazole-2-thiol and primary and secondary amines) that are connected via (a) a S oxidation/S-N coupling approach, (b) a S-N coupling/S-oxidation sequence, or via (c) a S-oxidation/S-F bond formation/SuFEx approach. The labile N-H bond in N-monoalkylated BT-sulfonamides (pKa (BTSO2N(H)Bn) = 3.34 ± 0.05) further allowed us to develop a simple weak base-promoted N-alkylation method and a stereoselective microwave-promoted Fukuyama-Mitsunobu reaction. N-Alkyl-N-aryl BT-sulfonamides were accessed with the help of the Chan-Lam coupling reaction. Developed methods were further used in stereo and chemoselective transformations of podophyllotoxin and several amino alcohols.
Collapse
Affiliation(s)
- František Zálešák
- Department of Organic Chemistry, Faculty of Science, Palacky University, tř. 17. listopadu 1192/12, CZ-771 46 Olomouc, Czech Republic
| | - Ondřej Kováč
- Department of Organic Chemistry, Faculty of Science, Palacky University, tř. 17. listopadu 1192/12, CZ-771 46 Olomouc, Czech Republic
| | - Eliška Lachetová
- Department of Organic Chemistry, Faculty of Science, Palacky University, tř. 17. listopadu 1192/12, CZ-771 46 Olomouc, Czech Republic
| | - Nikola Št'astná
- Department of Organic Chemistry, Faculty of Science, Palacky University, tř. 17. listopadu 1192/12, CZ-771 46 Olomouc, Czech Republic
| | - Jiří Pospíšil
- Department of Organic Chemistry, Faculty of Science, Palacky University, tř. 17. listopadu 1192/12, CZ-771 46 Olomouc, Czech Republic.,Laboratory of Growth Regulators, Palacky University & Institute of Experimental Botany AS CR, Šlechtitelů 27, CZ-783 71 Olomouc, Czech Republic
| |
Collapse
|
5
|
Le Roux A, Blaise É, Boudreault PL, Comeau C, Doucet A, Giarrusso M, Collin MP, Neubauer T, Kölling F, Göller AH, Seep L, Tshitenge DT, Wittwer M, Kullmann M, Hillisch A, Mittendorf J, Marsault E. Structure-Permeability Relationship of Semipeptidic Macrocycles-Understanding and Optimizing Passive Permeability and Efflux Ratio. J Med Chem 2020; 63:6774-6783. [PMID: 32453569 DOI: 10.1021/acs.jmedchem.0c00013] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
We herein report the first thorough analysis of the structure-permeability relationship of semipeptidic macrocycles. In total, 47 macrocycles were synthesized using a hybrid solid-phase/solution strategy, and then their passive and cellular permeability was assessed using the parallel artificial membrane permeability assay (PAMPA) and Caco-2 assay, respectively. The results indicate that semipeptidic macrocycles generally possess high passive permeability based on the PAMPA, yet their cellular permeability is governed by efflux, as reported in the Caco-2 assay. Structural variations led to tractable structure-permeability and structure-efflux relationships, wherein the linker length, stereoinversion, N-methylation, and peptoids site-specifically impact the permeability and efflux. Extensive nuclear magnetic resonance, molecular dynamics, and ensemble-based three-dimensional polar surface area (3D-PSA) studies showed that ensemble-based 3D-PSA is a good predictor of passive permeability.
Collapse
Affiliation(s)
- Antoine Le Roux
- Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada
| | - Émilie Blaise
- Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada
| | - Pierre-Luc Boudreault
- Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada
| | - Christian Comeau
- Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada
| | - Annie Doucet
- Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada
| | - Marilena Giarrusso
- Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada
| | | | - Thomas Neubauer
- Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany
| | - Florian Kölling
- Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany
| | - Andreas H Göller
- Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany
| | - Lea Seep
- Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany
| | | | - Matthias Wittwer
- Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany
| | | | | | | | - Eric Marsault
- Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada
| |
Collapse
|
6
|
Mei H, Han J, Klika KD, Izawa K, Sato T, Meanwell NA, Soloshonok VA. Applications of fluorine-containing amino acids for drug design. Eur J Med Chem 2019; 186:111826. [PMID: 31740056 DOI: 10.1016/j.ejmech.2019.111826] [Citation(s) in RCA: 119] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Revised: 10/21/2019] [Accepted: 10/26/2019] [Indexed: 01/26/2023]
Abstract
Fluorine-containing amino acids are becoming increasingly prominent in new drugs due to two general trends in the modern pharmaceutical industry. Firstly, the growing acceptance of peptides and modified peptides as drugs; and secondly, fluorine editing has become a prevalent protocol in drug-candidate optimization. Accordingly, fluorine-containing amino acids represent one of the more promising and rapidly developing areas of research in organic, bio-organic and medicinal chemistry. The goal of this Review article is to highlight the current state-of-the-art in this area by profiling 42 selected compounds that combine fluorine and amino acid structural elements. The compounds under discussion represent pharmaceutical drugs currently on the market, or in clinical trials as well as examples of drug-candidates that although withdrawn from development had a significant impact on the progress of medicinal chemistry and/or provided a deeper understanding of the nature and mechanism of biological action. For each compound, we present features of biological activity, a brief history of the design principles and the development of the synthetic approach, focusing on the source of tailor-made amino acid structures and fluorination methods. General aspects of the medicinal chemistry of fluorine-containing amino acids and synthetic methodology are briefly discussed.
Collapse
Affiliation(s)
- Haibo Mei
- College of Chemical Engineering, Nanjing Forestry University, Nanjing, 210037, China
| | - Jianlin Han
- College of Chemical Engineering, Nanjing Forestry University, Nanjing, 210037, China
| | - Karel D Klika
- Molecular Structure Analysis, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
| | - Kunisuke Izawa
- Hamari Chemicals Ltd., 1-4-29 Kunijima, Higashi-Yodogawa-ku, Osaka, 533-0024, Japan.
| | - Tatsunori Sato
- Hamari Chemicals Ltd., 1-4-29 Kunijima, Higashi-Yodogawa-ku, Osaka, 533-0024, Japan
| | - Nicholas A Meanwell
- Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ, 08543-4000, United States.
| | - Vadim A Soloshonok
- Department of Organic Chemistry I, University of the Basque Country UPV/EHU, Paseo Manuel Lardizábal 3, 20018, San Sebastián, Spain; IKERBASQUE, Basque Foundation for Science, María Díaz de Haro 3, Plaza Bizkaia, 48013, Bilbao, Spain.
| |
Collapse
|
7
|
Mortensen KT, Osberger TJ, King TA, Sore HF, Spring DR. Strategies for the Diversity-Oriented Synthesis of Macrocycles. Chem Rev 2019; 119:10288-10317. [DOI: 10.1021/acs.chemrev.9b00084] [Citation(s) in RCA: 72] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Kim T. Mortensen
- Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K
| | - Thomas J. Osberger
- Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K
| | - Thomas A. King
- Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K
| | - Hannah F. Sore
- Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K
| | - David R. Spring
- Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K
| |
Collapse
|
8
|
Abstract
This review describes a selection of macrocyclic natural products and structurally modified analogs containing peptidic and non-peptidic elements as structural features that potentially modulate cellular permeability. Examples range from exclusively peptidic structures like cyclosporin A or phepropeptins to compounds with mostly non-peptidic character, such as telomestatin or largazole. Furthermore, semisynthetic approaches and synthesis platforms to generate general and focused libraries of compounds at the interface of cyclic peptides and non-peptidic macrocycles are discussed.
Collapse
|
9
|
Zheng Y, Song W, Zhu Y, Wei B, Xuan L. Pd-Catalyzed Acetoxylation of γ-C(sp3)–H Bonds of Amines Directed by a Removable Bts-Protecting Group. J Org Chem 2018; 83:2448-2454. [DOI: 10.1021/acs.joc.7b02995] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Yong Zheng
- State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China
| | - Weibin Song
- State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China
| | - Yefu Zhu
- State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China
| | - Bole Wei
- State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China
| | - Lijiang Xuan
- State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China
| |
Collapse
|
10
|
Alihodžić S, Bukvić M, Elenkov IJ, Hutinec A, Koštrun S, Pešić D, Saxty G, Tomašković L, Žiher D. Current Trends in Macrocyclic Drug Discovery and beyond -Ro5. PROGRESS IN MEDICINAL CHEMISTRY 2018; 57:113-233. [DOI: 10.1016/bs.pmch.2018.01.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
11
|
Saupe J, Kunz O, Haustedt LO, Jakupovic S, Mang C. MacroEvoLution: A New Method for the Rapid Generation of Novel Scaffold-Diverse Macrocyclic Libraries. Chemistry 2017; 23:11784-11791. [PMID: 28715083 PMCID: PMC5601232 DOI: 10.1002/chem.201703209] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Indexed: 01/06/2023]
Abstract
Macrocycles are a structural class bearing great promise for future challenges in medicinal chemistry. Nevertheless, there are few flexible approaches for the rapid generation of structurally diverse macrocyclic compound collections. Here, an efficient method for the generation of novel macrocyclic peptide‐based scaffolds is reported. The process, named here as “MacroEvoLution”, is based on a cyclization screening approach that gives reliable access to novel macrocyclic architectures. Classification of building blocks into specific pools ensures that scaffolds with orthogonally addressable functionalities are generated, which can easily be used for the generation of structurally diverse compound libraries. The method grants rapid access to novel scaffolds with scalable synthesis (multi gram scale) and the introduction of further diversity at a late stage. Despite being developed for peptidic systems, the approach can easily be extended for the synthesis of systems with a decreased peptidic character.
Collapse
Affiliation(s)
- Jörn Saupe
- AnalytiCon Discovery GmbH, Hermannswerder Haus 17, 14473, Potsdam, Germany
| | - Oliver Kunz
- AnalytiCon Discovery GmbH, Hermannswerder Haus 17, 14473, Potsdam, Germany
| | - Lars Ole Haustedt
- AnalytiCon Discovery GmbH, Hermannswerder Haus 17, 14473, Potsdam, Germany
| | - Sven Jakupovic
- AnalytiCon Discovery GmbH, Hermannswerder Haus 17, 14473, Potsdam, Germany
| | - Christian Mang
- AnalytiCon Discovery GmbH, Hermannswerder Haus 17, 14473, Potsdam, Germany
| |
Collapse
|
12
|
Hopkins BA, Smith GF, Sciammetta N. Synthesis of Cyclic Peptidomimetics via a Pd-Catalyzed Macroamination Reaction. Org Lett 2016; 18:4072-5. [DOI: 10.1021/acs.orglett.6b01961] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Brett A. Hopkins
- Discovery Chemistry, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Graham F. Smith
- Discovery Chemistry, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Nunzio Sciammetta
- Discovery Chemistry, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| |
Collapse
|
13
|
Treder AP, Hickey JL, Tremblay MCJ, Zaretsky S, Scully CCG, Mancuso J, Doucet A, Yudin AK, Marsault E. Solid-Phase Parallel Synthesis of Functionalised Medium-to-Large Cyclic Peptidomimetics through Three-Component Coupling Driven by Aziridine Aldehyde Dimers. Chemistry 2015; 21:9249-55. [PMID: 26014974 DOI: 10.1002/chem.201500068] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2015] [Indexed: 11/06/2022]
Abstract
The first solid-phase parallel synthesis of macrocyclic peptides using three-component coupling driven by aziridine aldehyde dimers is described. The method supports the synthesis of 9- to 18-membered aziridine-containing macrocycles, which are then functionalized by nucleophilic opening of the aziridine ring. This constitutes a robust approach for the rapid parallel synthesis of macrocyclic peptides.
Collapse
Affiliation(s)
- Adam P Treder
- Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e av nord Sherbrooke (QC) J1H 5N4 (Canada)
| | - Jennifer L Hickey
- Davenport Research Laboratories, Department of Chemistry, University of Toronto, 80 St. George Street, Toronto (ON) M5S 3H6 (Canada)
| | - Marie-Claude J Tremblay
- Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e av nord Sherbrooke (QC) J1H 5N4 (Canada)
| | - Serge Zaretsky
- Davenport Research Laboratories, Department of Chemistry, University of Toronto, 80 St. George Street, Toronto (ON) M5S 3H6 (Canada)
| | - Conor C G Scully
- Davenport Research Laboratories, Department of Chemistry, University of Toronto, 80 St. George Street, Toronto (ON) M5S 3H6 (Canada)
| | - John Mancuso
- Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e av nord Sherbrooke (QC) J1H 5N4 (Canada)
| | - Annie Doucet
- Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e av nord Sherbrooke (QC) J1H 5N4 (Canada)
| | - Andrei K Yudin
- Davenport Research Laboratories, Department of Chemistry, University of Toronto, 80 St. George Street, Toronto (ON) M5S 3H6 (Canada)
| | - Eric Marsault
- Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e av nord Sherbrooke (QC) J1H 5N4 (Canada).
| |
Collapse
|
14
|
Mendive-Tapia L, Preciado S, García J, Ramón R, Kielland N, Albericio F, Lavilla R. New peptide architectures through C-H activation stapling between tryptophan-phenylalanine/tyrosine residues. Nat Commun 2015; 6:7160. [PMID: 25994485 PMCID: PMC4455059 DOI: 10.1038/ncomms8160] [Citation(s) in RCA: 210] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Accepted: 04/10/2015] [Indexed: 12/22/2022] Open
Abstract
Natural peptides show high degrees of specificity in their biological action. However, their therapeutical profile is severely limited by their conformational freedom and metabolic instability. Stapled peptides constitute a solution to these problems and access to these structures lies on a limited number of reactions involving the use of non-natural amino acids. Here, we describe a synthetic strategy for the preparation of unique constrained peptides featuring a covalent bond between tryptophan and phenylalanine or tyrosine residues. The preparation of such peptides is achieved in solution and on solid phase directly from the corresponding sequences having an iodo-aryl amino acid through an intramolecular palladium-catalysed C–H activation process. Moreover, complex topologies arise from the internal stapling of cyclopeptides and double intramolecular arylations within a linear peptide. Finally, as a proof of principle, we report the application to this new stapling method to relevant biologically active compounds. Macrocyclic, constrained peptides show promise in therapeutic applications due to the stable and defined conformations that can be produced. Here, the authors report a method to form macrocyclic peptides through C–H activation on tryptophan and coupling with iodo-substituted aryl amino acids
Collapse
Affiliation(s)
- Lorena Mendive-Tapia
- 1] Institute for Research in Biomedicine, Barcelona Science Park, Baldiri Reixac 10-12, 08028 Barcelona, Spain [2] Department of Organic Chemistry, University of Barcelona, Martí i Franqués 1-11, 08028 Barcelona, Spain [3] CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine
| | - Sara Preciado
- Department of Organic Chemistry, University of Barcelona, Martí i Franqués 1-11, 08028 Barcelona, Spain
| | - Jesús García
- Institute for Research in Biomedicine, Barcelona Science Park, Baldiri Reixac 10-12, 08028 Barcelona, Spain
| | - Rosario Ramón
- Barcelona Science Park, Baldiri Reixac 10-12, 08028 Barcelona, Spain
| | - Nicola Kielland
- Barcelona Science Park, Baldiri Reixac 10-12, 08028 Barcelona, Spain
| | - Fernando Albericio
- 1] Institute for Research in Biomedicine, Barcelona Science Park, Baldiri Reixac 10-12, 08028 Barcelona, Spain [2] Department of Organic Chemistry, University of Barcelona, Martí i Franqués 1-11, 08028 Barcelona, Spain [3] CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine [4] School of Chemistry, Yachay Tech, Yachay City of Knowledge, 100119 Urcuqui, Ecuador
| | - Rodolfo Lavilla
- 1] Barcelona Science Park, Baldiri Reixac 10-12, 08028 Barcelona, Spain [2] Laboratory of Organic Chemistry, Faculty of Pharmacy, University of Barcelona, Avda. Joan XXII s.n., 08028 Barcelona, Spain
| |
Collapse
|
15
|
Isidro-Llobet A, Hadje Georgiou K, Galloway WRJD, Giacomini E, Hansen MR, Méndez-Abt G, Tan YS, Carro L, Sore HF, Spring DR. A diversity-oriented synthesis strategy enabling the combinatorial-type variation of macrocyclic peptidomimetic scaffolds. Org Biomol Chem 2015; 13:4570-80. [PMID: 25778821 PMCID: PMC4441267 DOI: 10.1039/c5ob00371g] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Accepted: 03/11/2015] [Indexed: 01/23/2023]
Abstract
Macrocyclic peptidomimetics are associated with a broad range of biological activities. However, despite such potentially valuable properties, the macrocyclic peptidomimetic structural class is generally considered as being poorly explored within drug discovery. This has been attributed to the lack of general methods for producing collections of macrocyclic peptidomimetics with high levels of structural, and thus shape, diversity. In particular, there is a lack of scaffold diversity in current macrocyclic peptidomimetic libraries; indeed, the efficient construction of diverse molecular scaffolds presents a formidable general challenge to the synthetic chemist. Herein we describe a new, advanced strategy for the diversity-oriented synthesis (DOS) of macrocyclic peptidomimetics that enables the combinatorial variation of molecular scaffolds (core macrocyclic ring architectures). The generality and robustness of this DOS strategy is demonstrated by the step-efficient synthesis of a structurally diverse library of over 200 macrocyclic peptidomimetic compounds, each based around a distinct molecular scaffold and isolated in milligram quantities, from readily available building-blocks. To the best of our knowledge this represents an unprecedented level of scaffold diversity in a synthetically derived library of macrocyclic peptidomimetics. Cheminformatic analysis indicated that the library compounds access regions of chemical space that are distinct from those addressed by top-selling brand-name drugs and macrocyclic natural products, illustrating the value of our DOS approach to sample regions of chemical space underexploited in current drug discovery efforts. An analysis of three-dimensional molecular shapes illustrated that the DOS library has a relatively high level of shape diversity.
Collapse
Affiliation(s)
- Albert Isidro-Llobet
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Rose TE, Lawson KV, Harran PG. Large ring-forming alkylations provide facile access to composite macrocycles. Chem Sci 2015; 6:2219-2223. [PMID: 28694951 PMCID: PMC5485560 DOI: 10.1039/c4sc03848g] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Accepted: 02/05/2015] [Indexed: 11/21/2022] Open
Abstract
Macrocyclic compounds have potential to enable drug discovery for protein targets with extended, solvent-exposed binding sites. Crystallographic structures of peptides bound at such sites show strong surface complementarity and frequent aromatic side-chain contacts. In an effort to capture these features in stabilized small molecules, we describe a method to convert linear peptides into constrained macrocycles based upon their aromatic content. Designed templates initiate the venerable Friedel-Crafts alkylation to form large rings efficiently at room temperature - routinely within minutes - and unimpeded by polar functional groups. No protecting groups, metals, or air-free techniques are required. Regiochemistry can be tuned electronically to explore diverse macrocycle connectivities. Templates with additional reaction capabilities can further manipulate macrocycle structure. The chemistry lays a foundation to extend studies of how the size, shape and constitution of peptidyl macrocycles correlate with their pharmacological properties.
Collapse
Affiliation(s)
- Tristan E Rose
- Department of Chemistry and Biochemistry , University of California Los Angeles , 607 Charles E. Young Drive East , Los Angeles , USA .
| | - Kenneth V Lawson
- Department of Chemistry and Biochemistry , University of California Los Angeles , 607 Charles E. Young Drive East , Los Angeles , USA .
| | - Patrick G Harran
- Department of Chemistry and Biochemistry , University of California Los Angeles , 607 Charles E. Young Drive East , Los Angeles , USA .
| |
Collapse
|
17
|
Tsomaia N. Peptide therapeutics: Targeting the undruggable space. Eur J Med Chem 2015; 94:459-70. [DOI: 10.1016/j.ejmech.2015.01.014] [Citation(s) in RCA: 214] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Revised: 01/07/2015] [Accepted: 01/08/2015] [Indexed: 01/04/2023]
|
18
|
Yudin AK. Macrocycles: lessons from the distant past, recent developments, and future directions. Chem Sci 2015; 6:30-49. [PMID: 28553456 PMCID: PMC5424464 DOI: 10.1039/c4sc03089c] [Citation(s) in RCA: 322] [Impact Index Per Article: 35.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2014] [Accepted: 11/01/2014] [Indexed: 12/20/2022] Open
Abstract
A noticeable increase in molecular complexity of drug targets has created an unmet need in the therapeutic agents that are larger than traditional small molecules. Macrocycles, which are cyclic compounds comprising 12 atoms or more, are now recognized as molecules that "are up to the task" to interrogate extended protein interfaces. However, because macrocycles (particularly the ones based on peptides) are equipped with large polar surface areas, achieving cellular permeability and bioavailability is anything but straightforward. While one might consider this to be the Achilles' heel of this class of compounds, the synthetic community continues to develop creative approaches toward the synthesis of macrocycles and their site-selective modification. This perspective provides an overview of both mechanistic and structural issues that bear on macrocycles as a unique class of molecules. The reader is offered a historical foray into some of the classic studies that have resulted in the current renaissance of macrocycles. In addition, an attempt is made to overview the more recent developments that give hope that macrocycles might indeed turn into a useful therapeutic modality.
Collapse
Affiliation(s)
- Andrei K Yudin
- Department of Chemistry , University of Toronto , 80 St. George Street , Toronto , Ontario M5S 3H6 , Canada . ; Blog: http://www.amphoteros.com
| |
Collapse
|
19
|
Ermert P, Moehle K, Obrecht D. Macrocyclic Inhibitors of GPCR's, Integrins and Protein–Protein Interactions. MACROCYCLES IN DRUG DISCOVERY 2014. [DOI: 10.1039/9781782623113-00283] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
This chapter summarizes some highlights of macrocyclic drug discovery in the area of GPCRs, integrins, and protein–protein interactions spanning roughly the last 30 years. Several examples demonstrate that incorporation of pharmacophores derived from natural peptide ligands into the context of a constrained macrocycle (“lock of the bioactive conformation”) has proven a powerful approach for the discovery of potent and selective macrocyclic drugs. In addition, it will be shown that macrocycles, due to their semi-rigid nature, can exhibit unique properties that can be beneficially exploited by medicinal chemists. Macrocycles can adapt their conformation during binding to a flexible protein target surface (“induced fit”), and due to their size, can interact with larger protein interfaces (“hot spots”). Also, macrocycles can display favorable ADME properties well beyond the rule of 5 in particular exhibiting favorable cell penetrating properties and oral bioavailability.
Collapse
Affiliation(s)
- Philipp Ermert
- Polyphor Ltd Hegenheimermattweg 125 CH-4123 Allschwil Switzerland
| | - Kerstin Moehle
- University of Zurich Winterthurerstrasse 190 CH-8057 Zurich Switzerland
| | - Daniel Obrecht
- Polyphor Ltd Hegenheimermattweg 125 CH-4123 Allschwil Switzerland
| |
Collapse
|
20
|
Vopat BG, Murali J, Gowda AL, Kaback L, Blaine T. The global percutaneous shuttling technique tip for arthroscopic rotator cuff repair. Orthop Rev (Pavia) 2014; 6:5279. [PMID: 25002932 PMCID: PMC4083305 DOI: 10.4081/or.2014.5279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2014] [Revised: 02/23/2014] [Accepted: 02/26/2014] [Indexed: 11/22/2022] Open
Abstract
Most arthroscopic rotator cuff repairs utilize suture passing devices placed through arthroscopic cannulas. These devices are limited by the size of the passing device where the suture is passed through the tendon. An alternative technique has been used in the senior author’s practice for the past ten years, where sutures are placed through the rotator cuff tendon using percutaneous passing devices. This technique, dubbed the global percutaneous shuttling technique of rotator cuff repair, affords the placement of sutures from nearly any angle and location in the shoulder, and has the potential advantage of larger suture bites through the tendon edge. These advantages may increase the area of tendon available to compress to the rotator cuff footprint and improve tendon healing and outcomes. The aim of this study is to describe the global percutaneous shuttling (GPS) technique and report our results using this method. The GPS technique can be used for any full thickness rotator cuff tear and is particularly useful for massive cuff tears with poor tissue quality. We recently followed up 22 patients with an average follow up of 32 months to validate its usefulness. American Shoulder and Elbow Surgeons scores improved significantly from 37 preoperatively to 90 postoperatively (P<0.0001). This data supports the use of the GPS technique for arthroscopic rotator cuff repair. Further biomechanical studies are currently being performed to assess the improvements in tendon footprint area with this technique.
Collapse
Affiliation(s)
- Bryan G Vopat
- Orthopedic Department, Warren Alpert School of Medicine at Brown University, Rhode Island Hospital , Providence, RI, USA
| | - Jothi Murali
- Orthopedic Department, Warren Alpert School of Medicine at Brown University, Rhode Island Hospital , Providence, RI, USA
| | - Ashok L Gowda
- Orthopedic Department, Yale School of Medicine , New Haven, CT, USA
| | - Lee Kaback
- Shoulder and Elbow Surgery , OrthoNY, Albany, NY, USA
| | - Theodore Blaine
- Orthopedic Department, Yale School of Medicine , New Haven, CT, USA
| |
Collapse
|
21
|
Template-constrained macrocyclic peptides prepared from native, unprotected precursors. Proc Natl Acad Sci U S A 2013; 110:E3753-60. [PMID: 24043790 DOI: 10.1073/pnas.1311706110] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Peptide-protein interactions are important mediators of cellular-signaling events. Consensus binding motifs (also known as short linear motifs) within these contacts underpin molecular recognition, yet have poor pharmacological properties as discrete species. Here, we present methods to transform intact peptides into stable, templated macrocycles. Two simple steps install the template. The key reaction is a palladium-catalyzed macrocyclization. The catalysis has broad scope and efficiently forms large rings by engaging native peptide functionality including phenols, imidazoles, amines, and carboxylic acids without the necessity of protecting groups. The tunable reactivity of the template gives the process special utility. Defined changes in reaction conditions markedly alter chemoselectivity. In all cases examined, cyclization occurs rapidly and in high yield at room temperature, regardless of peptide composition or chain length. We show that conformational restraints imparted by the template stabilize secondary structure and enhance proteolytic stability in vitro. Palladium-catalyzed internal cinnamylation is a strong complement to existing methods for peptide modification.
Collapse
|
22
|
Scully CCG, Rai V, Poda G, Zaretsky S, Burns DC, Houliston RS, Lou T, Yudin AK. Bending Rigid Molecular Rods: Formation of Oligoproline Macrocycles. Chemistry 2012; 18:15612-7. [DOI: 10.1002/chem.201203266] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2012] [Indexed: 12/14/2022]
|
23
|
Hoveyda HR, Marsault E, Gagnon R, Mathieu AP, Vézina M, Landry A, Wang Z, Benakli K, Beaubien S, Saint-Louis C, Brassard M, Pinault JF, Ouellet L, Bhat S, Ramaseshan M, Peng X, Foucher L, Beauchemin S, Bhérer P, Veber DF, Peterson ML, Fraser GL. Optimization of the Potency and Pharmacokinetic Properties of a Macrocyclic Ghrelin Receptor Agonist (Part I): Development of Ulimorelin (TZP-101) from Hit to Clinic. J Med Chem 2011; 54:8305-20. [DOI: 10.1021/jm2007062] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Hamid R. Hoveyda
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Eric Marsault
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - René Gagnon
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Axel P. Mathieu
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Martin Vézina
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Annick Landry
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Zhigang Wang
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Kamel Benakli
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Sylvie Beaubien
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Carl Saint-Louis
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Martin Brassard
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | | | - Luc Ouellet
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Shridhar Bhat
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Mahesh Ramaseshan
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Xiaowen Peng
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Laurence Foucher
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Sophie Beauchemin
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Patrick Bhérer
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Daniel F. Veber
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Mark L. Peterson
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Graeme L. Fraser
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| |
Collapse
|
24
|
Abstract
Peptide macrocycles have found applications that range from drug discovery to nanomaterials. These ring-shaped molecules have shown remarkable capacity for functional fine-tuning. Such capacity is enabled by the possibility of adjusting the peptide conformation using the techniques of chemical synthesis. Cyclic peptides have been difficult, and often impossible, to prepare using traditional synthetic methods. For macrocyclization to occur, the activated peptide must adopt an entropically disfavoured pre-cyclization conformation before forming the desired product. Here, we review recent solutions to some of the major challenges in this important area of contemporary synthesis.
Collapse
|
25
|
Marsault E, Peterson ML. Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery. J Med Chem 2011; 54:1961-2004. [DOI: 10.1021/jm1012374] [Citation(s) in RCA: 591] [Impact Index Per Article: 45.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Eric Marsault
- Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke Québec, J1H5N4, Canada
| | - Mark L. Peterson
- Tranzyme Pharma Inc., 3001 12e Avenue Nord, Sherbrooke, Québec, J1H5N4, Canada
| |
Collapse
|
26
|
Bornholdt J, Felding J, Clausen RP, Kristensen JL. Ring opening of pymisyl-protected aziridines with organocuprates. Chemistry 2011; 16:12474-80. [PMID: 20839183 DOI: 10.1002/chem.201001026] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The pyrimidine-2-sulfonyl (pymisyl) group is introduced as a new protecting group that can be used to activate aziridines towards ring opening. It is readily introduced and removed under mild conditions. Regioselective ring opening of pymisyl-protected 2-methyl-aziridine with organocuprates gives the corresponding sulfonamides in high yields, and the pymisyl group can subsequently be removed upon treatment with a thiolate. The versatility of this new nitrogen protecting group is illustrated with a new synthesis of Selegiline, a monoamine oxidase-B inhibitor marketed for the treatment of Parkinson's disease.
Collapse
Affiliation(s)
- Jan Bornholdt
- Department of Medicinal Chemistry, University of Copenhagen, Faculty of Pharmaceutical Sciences, Universitetsparken 2, 2100 Copenhagen, Denmark
| | | | | | | |
Collapse
|
27
|
Terrett NK. Methods for the synthesis of macrocycle libraries for drug discovery. DRUG DISCOVERY TODAY. TECHNOLOGIES 2010; 7:e95-e146. [PMID: 24103719 DOI: 10.1016/j.ddtec.2010.06.002] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
|